Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript January 30, 2024 Dr. Reddy’s Laboratories Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good day, and welcome to the Dr. Reddy’s Q3 FY ’24 Earnings […]
Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
HYDERABAD, India, January 31, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
HYDERABAD, India & PRINCETON, N.J., January 03, 2024--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women’s health and dietary supplements portfolio of brands.
HYDERABAD, India, December 14, 2023--Dr. Reddy’s has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agenda.